US late-stage biotech Rocket Pharmaceuticals (Nasdaq: RCKT) saw its shares plummet as much as 64% to $2.25 in pre-market ...

In a groundbreaking scientific achievement, the Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir ...

The gene editing was performed using CRISPR-Cas9 technology and adhered to international biosafety protocols. Importantly, ...

The edited sheep contains no foreign DNA, distinguishing it from transgenic organisms and paving the way for regulatory ...

SKUAST-Kashmir researchers create India's first gene-edited sheep, using CRISPR-Cas9 technology for enhanced muscle growth, marking a significant milestone in animal biotechnology.

Srinagar- Researchers at the Sher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST) here have produced ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated ...

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease: Cranbury, New Jersey Wednesday, May 28, 2025, 14:00 Hrs [IST] Rocket P ...

The New Food Forum conference held in Prague last week brought together key stakeholders from the Czech retail sector and ...

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

The antibody market has become a cornerstone of modern biotechnology and pharmaceutical industries, underpinning a vast array of diagnostic and therapeutic applications. Antibodies, which are proteins ...